Rigel Pharmaceuticals Enters Collaboration and License Agreement with Grifols, S.A. to Commercialize Fostamatinib in Europe

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. ABBV
3. MU
4. META
5. IBM
6. PRIM
7. SPY
8. ACN
9. NVDA
10. BLZE

Go back to Rigel Pharmaceuticals Enters Collaboration and License Agreement with Grifols, S.A. to Commercialize Fostamatinib in Europe

Rigel Pharmaceuticals (RIGL) PT Raised to $11 at BMO Capital

January 23, 2019 1:15 PM EST

BMO Capital analyst Do Kim raised the price target on Rigel Pharmaceuticals (NASDAQ: RIGL) to $11.00 (from $10.00) while maintaining a Outperform rating.

Kim commented, "We believe the signing of a European partner represents an important milestone, as it provides non-dilutive financing as well as additional... More